Physician profile
Jonathan Field
NPI 1578547006
$62,369.36
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $1,439 · 2021: $3,174 · 2022: $6,757 · 2023: $2,935 · 2024: $3,638 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $11K · Travel and Lodging: $2,163 · Education: $187 · Honoraria: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,738.50 |
| Food and Beverage | $10,968.10 |
| Travel and Lodging | $2,162.91 |
| Education | $187.26 |
| Honoraria | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22,434.46 | 2019-2023 | Xolair |
| Ionis Pharmaceuticals, INC. | $12,395.43 | 2025 | Dawnzera |
| Genzyme Corporation | $5,814.68 | 2019-2025 | |
| Csl Behring | $5,794.48 | 2019-2025 | Andembry, Haegarda, Kcentra |
| Glaxosmithkline, LLC. | $3,890.46 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,667.35 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $1,781.01 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $1,156.36 | 2021-2025 | Orladeyo |
| Pfizer INC. | $912.94 | 2019-2025 | |
| Abbvie INC. | $702.78 | 2023-2024 | |
| Grifols USA, LLC | $611.21 | 2020-2025 | Xembify |
| Kaleo, INC. | $594.35 | 2020-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $572.81 | 2020-2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $433.66 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $329.92 | 2020-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $327.92 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $280.56 | 2020-2025 | Takhzyro |
| Allergan, INC. | $275.00 | 2019 | |
| Aimmune Therapeutics, INC. | $266.11 | 2020-2024 | |
| Blueprint Medicines Corporation | $174.34 | 2022-2025 | Ayvakit |
| Organon LLC | $137.34 | 2025 | Vtama |
| Greer Laboratories, INC. | $120.55 | 2019 | |
| Mylan Specialty L.P. | $104.78 | 2019 | |
| Incyte Corporation | $92.32 | 2022-2025 | Opzelura |
| Pharming Healthcare, INC. | $74.06 | 2020-2022 | |
| Alk-Abello, INC | $56.92 | 2019-2022 | |
| Shire North American Group INC | $52.55 | 2019 | |
| Galderma Laboratories, L.P. | $46.29 | 2025 | Nemluvio |
| Covis Pharma Gmbh | $44.32 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $39.13 | 2025 | Neffy |
| Lilly USA, LLC | $35.19 | 2024-2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $35.04 | 2024 | Ryaltris |
| Octapharma USA, INC. | $33.41 | 2019-2022 | |
| Cipher Pharmaceuticals US LLC | $33.25 | 2025 | Spinosad, Natroba |
| Optinose US, INC. | $30.57 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $17.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.